stem-cells-istock-577639302_posteriori

posteriori / iStockphoto.com

26 February 2018Americas

Kite teams up with Sangamo to treat cancer

Kite Pharma has entered into a collaboration with Sangamo Therapeutics that will see the companies develop next-generation engineered cell therapies to treat cancer.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Sangamo acquires biotech company for $84m

25 July 2018 California-based Sangamo Therapeutics has acquired biotech company TxCell for approximately €72 million.

Gilead follows Kite acquisition with $567m buy

12 December 2017 Gilead Sciences has built on its acquisition of cell therapy company Kite Pharma with another purchase.

Kite accused of infringing Juno’s cancer immunotherapy

5 September 2017 Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have entered a second round of litigation against Kite, a company which specialises in cancer immunotherapy treatments.

More on this story

Sangamo acquires biotech company for $84m

25 July 2018 California-based Sangamo Therapeutics has acquired biotech company TxCell for approximately €72 million.

Gilead follows Kite acquisition with $567m buy

12 December 2017 Gilead Sciences has built on its acquisition of cell therapy company Kite Pharma with another purchase.

Kite accused of infringing Juno’s cancer immunotherapy

5 September 2017 Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have entered a second round of litigation against Kite, a company which specialises in cancer immunotherapy treatments.

More on this story

Sangamo acquires biotech company for $84m

25 July 2018 California-based Sangamo Therapeutics has acquired biotech company TxCell for approximately €72 million.

Gilead follows Kite acquisition with $567m buy

12 December 2017 Gilead Sciences has built on its acquisition of cell therapy company Kite Pharma with another purchase.

Kite accused of infringing Juno’s cancer immunotherapy

5 September 2017 Juno Therapeutics and the Sloan Kettering Institute for Cancer Research have entered a second round of litigation against Kite, a company which specialises in cancer immunotherapy treatments.

More features

WATCH: The transparency tightrope—balancing innovation, regulation, and IP protection in a new era

Chicago firm Much Shelist adds partner with ‘entrepreneurial mindset’

Powell Gilbert launches Düsseldorf office with leading patent litigator

Startups toolkit: Why investors want more than patents

J&J fends off generic schizophrenia drug bids

Kilpatrick adds ‘seasoned litigator’ as trademark partner

WATCH: An update on EPO Board of Appeal strategy for 2025 and beyond

Startup challenges rival over brain monitoring tech at ITC